Phase 2 testing of Cyteir's lead cancer drug candidate later is slated to start later this year. The Series C round of funding includes crossover investors, whose involvement is a sign a biotech is preparing for an IPO.
Rather than manually entering their username and password every time they utilize a device, Imprivata Mobile Device Access lets clinicians tap their badge to a mobile device, then single sign-on into their applications.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Agile Therapeutics released "positive top-line phase 3 results" on Tuesday, but the market did not buy it. Its shares plummeted 74 percent, trumping the 68 percent drop inflicted upon Inotek Pharmaceuticals earlier in the day.